Zhiheng Xu

Bldg 5, 720 Cailun Road
Shanghai, 201203, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 28 publications

An exploratory 18F-Florzolotau tau PET study in putative body-first versus brain-first Parkinson's disease.

An exploratory 18F-Florzolotau tau PET study in putative body-first versus brain-first Parkinson's disease.

Journal: European journal of nuclear medicine and molecular imaging

Published: April 21, 2026

Discovery of Naphthyridinone Derivatives as Selective PKMYT1/WEE1 Dual Inhibitors for Cancer Therapy.

Discovery of Naphthyridinone Derivatives as Selective PKMYT1/WEE1 Dual Inhibitors for Cancer Therapy.

Journal: Journal of medicinal chemistry

Published: April 20, 2026

Combined impact of depressive symptoms and mild cognitive impairment on Parkinson's disease progression.

Combined impact of depressive symptoms and mild cognitive impairment on Parkinson's disease progression.

Journal: Parkinsonism & related disorders

Published: April 11, 2026

Putative sympathetic-predominant subtype in body-first Parkinson's disease is associated with accelerated cognitive decline.

Putative sympathetic-predominant subtype in body-first Parkinson's disease is associated with accelerated cognitive decline.

Journal: Frontiers in aging neuroscience

Published: November 17, 2025

Discovery of Naphthyridinone Derivatives as Selective and Potent PKMYT1 Inhibitors with Antitumor Efficacy.

Discovery of Naphthyridinone Derivatives as Selective and Potent PKMYT1 Inhibitors with Antitumor Efficacy.

Journal: Journal of medicinal chemistry

Published: April 08, 2025

Evaluating the Clinical Utility of a Machine Learning Model for Diagnosing Parkinson's Disease Using Acoustic Parameters.

Evaluating the Clinical Utility of a Machine Learning Model for Diagnosing Parkinson's Disease Using Acoustic Parameters.

Journal: Journal of voice : official journal of the Voice Foundation

Published: December 25, 2024

Plasma GFAP and NfL associate with cerebral glucose metabolism in putative brain-first and body-first Parkinson's disease subtypes.

Plasma GFAP and NfL associate with cerebral glucose metabolism in putative brain-first and body-first Parkinson's disease subtypes.

Journal: NPJ Parkinson's disease

Published: August 04, 2024

Disease progression in proposed brain-first and body-first Parkinson's disease subtypes.

Disease progression in proposed brain-first and body-first Parkinson's disease subtypes.

Journal: NPJ Parkinson's disease

Published: January 29, 2024

Discovery of 4,5,6,7-Tetrahydropyrazolo[1.5-a]pyrizine Derivatives as Core Protein Allosteric Modulators (CpAMs) for the Inhibition of Hepatitis B Virus.

Discovery of 4,5,6,7-Tetrahydropyrazolo[1.5-a]pyrizine Derivatives as Core Protein Allosteric Modulators (CpAMs) for the Inhibition of Hepatitis B Virus.

Journal: Journal of medicinal chemistry

Published: October 06, 2023

Using a smartphone-based self-management platform to study sex differences in Parkinson's disease: multicenter, cross-sectional pilot study.

Using a smartphone-based self-management platform to study sex differences in Parkinson's disease: multicenter, cross-sectional pilot study.

Journal: BMC medical informatics and decision making

Published: July 31, 2023

Discovery of a Series of Indane-Containing NBTIs with Activity against Multidrug-Resistant Gram-Negative Pathogens.

Discovery of a Series of Indane-Containing NBTIs with Activity against Multidrug-Resistant Gram-Negative Pathogens.

Journal: ACS medicinal chemistry letters

Published: May 04, 2023

Discovery of Linvencorvir (RG7907), a Hepatitis B Virus Core Protein Allosteric Modulator, for the Treatment of Chronic HBV Infection.

Discovery of Linvencorvir (RG7907), a Hepatitis B Virus Core Protein Allosteric Modulator, for the Treatment of Chronic HBV Infection.

Journal: Journal of medicinal chemistry

Published: March 10, 2023

Showing 1-12 of 28

Last Updated: 09/26/2026